RxDoctor Payments Data

Christopher Taylor, MD

Ophthalmology · Knoxville, TNNPI 1013911791

Payments from drug & device makers

$1,162in general payments, 2019–2025

Across 42 payments — averaging $27.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$231
  • AbbVie$222
  • Alcon$219
  • Bausch & Lomb Americas Inc.$83
  • Mallinckrodt Hospital Products Inc.$64
  • Novartis$63
  • plus $279 from 8 others

What the payments were for

  • Food & beverage$1,12697%
  • Gifts$373%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,162 in reported general payments places this provider in the 40th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$412,425
Medicare patients
1,158
Services billed
4,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine66$65,717
IlevroNepafenac66$24,368
RocklatanNetarsudil Mesylat/Latanoprost35$14,751
RhopressaNetarsudil Mesylate28$13,717
LumiganBimatoprost26$13,165
CombiganBrimonidine Tartrate/Timolol29$11,753
VyzultaLatanoprostene Bunod24$9,990
Prednisolone Acetate159$9,225
Latanoprost775$8,573
Brimonidine Tartrate109$3,789
Timolol Maleate236$2,791
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat147$2,391
MoxifloxacinMoxifloxacin Hcl58$1,883
Tobramycin307$1,739
ErythromycinErythromycin Base153$1,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$222$90,634121 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$32$28,46863 claims
NovartisIlevro$63$24,36866 claims
Bausch & Lomb Americas Inc.Vyzulta$83$9,99024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →